{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:57:12Z","timestamp":1782493032743,"version":"3.54.5"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T00:00:00Z","timestamp":1562889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immunosuppressive therapy for connective tissue diseases (CTDs) increases risk for opportunistic infections including Pneumocystis pneumonia (PCP). High mortality rates are reported in CTD patients with PCP, which suggests a potential need for prophylaxis, but indications remain poorly defined. Wide variations in the use of PCP prophylaxis among rheumatologists have been documented. This study evaluated PCP prophylaxis patterns for CTD patients among infectious disease (ID) physicians.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An electronic survey was emailed to 1264 adult ID physicians who are members of the Infectious Diseases Society of America Emerging Infections Network.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Six hundred thirty-one physicians responded to the survey. Respondents to the survey were more likely to work in academics (P = .02) and be early (&amp;lt;5 years) or late (\u226525 years) in their careers (P = .0002). Forty-three percent (n = 269) made no recommendations for PCP prophylaxis in non-HIV patients. Of the 362 respondents who did make such recommendations, the greatest consensus for disease-based prophylaxis was for granulomatosis with polyangiitis (53%). For therapy-based prophylaxis, corticosteroids \u226520 mg\/d was the most frequently cited indication (87%). Surrogate laboratory markers to aid in decisions about prophylaxis were not routinely used (21%). Although the majority recommended discontinuation of PCP prophylaxis with tapering of corticosteroids (65%), there was variability in the specific dose. Eighty-nine percent of respondents felt that guidelines about PCP prophylaxis would be helpful.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>There is little consensus about PCP prophylaxis in CTDs among ID physicians. Guidelines for PCP prophylaxis would be helpful when caring for these complex patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofz315","type":"journal-article","created":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T15:16:58Z","timestamp":1562944618000},"source":"Crossref","is-referenced-by-count":14,"title":["Practice Patterns of Pneumocystis Pneumonia Prophylaxis in Connective Tissue Diseases: A Survey of Infectious Disease Physicians"],"prefix":"10.1093","volume":"6","author":[{"given":"Rachel M","family":"Wolfe","sequence":"first","affiliation":[{"name":"Rheumatology and Immunology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E","family":"Beekmann","sequence":"additional","affiliation":[{"name":"Emerging Infections Network, University of Iowa, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M","family":"Polgreen","sequence":"additional","affiliation":[{"name":"Emerging Infections Network, University of Iowa, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L","family":"Winthrop","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Oregon Health and Sciences University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-005X","authenticated-orcid":false,"suffix":"Jr","given":"James E","family":"Peacock","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,12]]},"reference":[{"key":"2020081004072024000_CIT0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2020081004072024000_CIT0002","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"2020081004072024000_CIT0003","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/cid\/ciu185","article-title":"Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis","volume":"58","author":"Korbeti","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020081004072024000_CIT0004","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4065\/82.9.1052","article-title":"Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials","volume":"82","author":"Green","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"2020081004072024000_CIT0005","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005590.pub3","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2020081004072024000_CIT0006","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11926-017-0664-6","article-title":"Pneumocystis pneumonia and the rheumatologist: which patients are at risk and how can PCP be prevented?","volume":"19","author":"Wolfe","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"2020081004072024000_CIT0007","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/RHU.0b013e31817a7e30","article-title":"Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature","volume":"14","author":"Gupta","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"2020081004072024000_CIT0008","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3899\/jrheum.090843","article-title":"A survey of rheumatologists\u2019 practice for prescribing Pneumocystis prophylaxis","volume":"37","author":"Cettomai","year":"2010","journal-title":"J Rheumatol"},{"key":"2020081004072024000_CIT0009","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/cid\/cit932","article-title":"The Infectious Diseases Society of America Emerging Infections Network: bridging the gap between clinical infectious diseases and public health","volume":"58","author":"Pillai","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020081004072024000_CIT0010","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMra032588","article-title":"Pneumocystis pneumonia","volume":"350","author":"Thomas","year":"2004","journal-title":"N Engl J Med"},{"key":"2020081004072024000_CIT0011","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/myc.12636","article-title":"The changing trends and profile of pneumocystosis mortality in the United States, 1999\u20132014","volume":"60","author":"Wickramasekaran","year":"2017","journal-title":"Mycoses"},{"key":"2020081004072024000_CIT0012","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamainternmed.2018.2387","article-title":"Corticosteroid use and Pneumocystis pneumonia prophylaxis. A teachable moment","volume":"178","author":"LoPiccolo","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2020081004072024000_CIT0013"},{"key":"2020081004072024000_CIT0014","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020081004072024000_CIT0015","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2334-4-42","article-title":"Autoimmune inflammatory disorders, systemic corticosteroids and Pneumocystis pneumonia: a strategy for prevention","volume":"4","author":"Sowden","year":"2004","journal-title":"BMC Infect Dis"},{"key":"2020081004072024000_CIT0016","first-page":"795","article-title":"Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener\u2019s granulomatosis","volume":"151","author":"Ognibene","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"2020081004072024000_CIT0017","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/RHU.0000000000000215","article-title":"Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid","volume":"21","author":"Chew","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"2020081004072024000_CIT0018","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00124743-200004000-00007","article-title":"Pneumocystis carinii pneumonia prophylaxis in patients with rheumatic diseases undergoing immunosuppressive therapy: prevalence and associated features","volume":"6","author":"Vernovsky","year":"2000","journal-title":"J Clin Rheumatol"},{"key":"2020081004072024000_CIT0019","first-page":"490","article-title":"Guidelines for prophylaxis of Pneumocystis pneumonia cannot rely solely on CD4-cell count in autoimmune and inflammatory diseases","volume":"36","author":"Baulier","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2020081004072024000_CIT0020","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for Pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020081004072024000_CIT0021","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/annrheumdis-2017-212588","article-title":"Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); that is the question","volume":"77","author":"Winthrop","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020081004072024000_CIT0022","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofz315\/28931648\/ofz315.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/9\/ofz315\/33577018\/ofz315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/9\/ofz315\/33577018\/ofz315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T08:18:53Z","timestamp":1597047533000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofz315\/5531750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,12]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofz315","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9]]},"published":{"date-parts":[[2019,7,12]]},"article-number":"ofz315"}}